These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31594102)

  • 21. Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis: Sarcopenia and Nonalcoholic Fatty Liver Disease.
    Kawaguchi T; Takahashi H; Gerber LH
    Clin Liver Dis; 2023 May; 27(2):275-286. PubMed ID: 37024207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation.
    Carias S; Castellanos AL; Vilchez V; Nair R; Dela Cruz AC; Watkins J; Barrett T; Trushar P; Esser K; Gedaly R
    J Gastroenterol Hepatol; 2016 Mar; 31(3):628-33. PubMed ID: 26399838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarcopenia and fatty liver disease.
    Kim JA; Choi KM
    Hepatol Int; 2019 Nov; 13(6):674-687. PubMed ID: 31705444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study.
    Hong HC; Hwang SY; Choi HY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
    Hepatology; 2014 May; 59(5):1772-8. PubMed ID: 23996808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
    Wong CR; Nguyen MH; Lim JK
    World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sarcopenia in Liver Disease: Current Evidence and Issues to Be sResolved.
    Song M; Xia L; Liu Q; Sun M; Wang F; Yang C
    Adv Exp Med Biol; 2018; 1088():413-433. PubMed ID: 30390263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research advances in diagnosis of non-alcoholic fatty liver disease].
    Wang JH; Yu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):115-118. PubMed ID: 28297797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality.
    Younossi Z; Henry L
    Gastroenterology; 2016 Jun; 150(8):1778-85. PubMed ID: 26980624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report.
    Salsamendi J; Pereira K; Kang K; Fan J
    J Radiol Case Rep; 2015 Sep; 9(9):36-43. PubMed ID: 26629307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARCOPENIA AND SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE.
    Cruz JF; Ferrari YAC; Machado CP; Santana NN; Mota AVH; Lima SO
    Arq Gastroenterol; 2019; 56(4):357-360. PubMed ID: 31618396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.
    Polyzos SA; Vachliotis ID; Mantzoros CS
    Metabolism; 2023 Oct; 147():155676. PubMed ID: 37544590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease.
    Kang MK; Kim KO; Kim MC; Park JG; Jang BI
    Dig Dis; 2020; 38(6):507-514. PubMed ID: 32135539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sarcopenic obesity in fatty liver.
    Merli M; Lattanzi B; Aprile F
    Curr Opin Clin Nutr Metab Care; 2019 May; 22(3):185-190. PubMed ID: 30893090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.
    Cabrera D; Ruiz A; Cabello-Verrugio C; Brandan E; Estrada L; Pizarro M; Solis N; Torres J; Barrera F; Arrese M
    Dig Dis Sci; 2016 Nov; 61(11):3190-3198. PubMed ID: 27572941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
    Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
    Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.